Karen Krasney

EVP & General Counsel Karen Krasney sells 24,100 CAPR shares at $30.38 for $732.2K; retains 30.5K shares plus 31,261 option shares.

Karen Krasney, EVP and General Counsel, sold 24,100 shares at $30.38 on 2026-06-25, reducing her direct holdings from 54.6K to 30.5K shares (-44.1% of pre-transaction holdings). This is the third open-market sale of CAPR stock by this insider; her prior CAPR sale on 2026-05-01 showed a -5.5% 30-day return, and her 2026-03-31 sale posted a -21.0% 90-day return. The stock currently trades at $23.80, down -41.0% from the 52-week high of $40.37, and has declined -20.6% over the past 30 days. The company remains unprofitable with annual revenue growth of -100.0%, though the insider retains 31,261 shares through stock options plus 30.5K direct shares post-transaction.

EVP General Counsel sells ~45% of holdings while simultaneously purchasing shares; net exit amid stock recovery from lows.

Krasney Karen, the company's EVP and General Counsel, executed a paired transaction—buying and selling shares on the same day—that reveals a nuanced insider posture. She purchased a meaningful stake while simultaneously liquidating roughly half her total holdings, suggesting neither bullish conviction nor bearish panic, but rather portfolio rebalancing or tax-motivated trading. What's notable is the timing: the stock has recovered significantly from its lows and is trading below its year-to-date highs, yet this C-suite officer is trimming exposure rather than adding. Against the company's challenging fundamentals—operating at a substantial net loss with no current annual revenue—this selective exit from a senior executive raises a yellow flag about near-term confidence. The transaction itself is material enough to trigger SEC thresholds, but the paired buy-sell structure muddles the interpretive signal that a straightforward sale would convey.

EVP General Counsel Karen Krasney sells 25,000 shares at $30.12; 45.0% reduction in holdings amid unprofitable operations

Karen Krasney, EVP and General Counsel, sold 25,000 shares at $30.12 on 2026-03-31, reducing her post-transaction holdings to 30,547 shares from a pre-transaction position of 55,547 shares. This represents a -45.0% reduction in her stake. The sale occurs as CAPRICOR THERAPEUTICS operates with significant financial stress: the company reported a net income of $-24,570,647.00 for its most recent full fiscal year, while revenue contracted by -100.0% year-over-year in the latest quarter. The market cap is $1,732,220,326.20, yet the company remains deeply unprofitable, creating an asymmetry between market valuation and underlying operating losses. The transaction is executed at $30.12, positioned -10.3% from the 52-week high but +12.1% above the 30-day average, capturing a local strength moment for a material reduction in insider equity exposure.